… with IgG4-RD and 10 healthy individuals, all of whom underwent [ 18F]FAPI PET/CT. Organ-specific uptake thresholds were defined as [18F]F…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 169 of 2459…a family history of APS (37.5% vs. 17.5% ; p= 0.056). Comparing APS patients and aPL carriers, arterial (Odds ratio 109 CI95% 8.58-…
…teristics of SLE patientsConclusions In this real-world cohort, belimumab treatment was associated with significant improvements in disea…
…ibodies serve as key diagnostic and classification criteria for systemic lupus erythematosus(SLE). In addition to serving as markers of disease, some autoan…
…et classification criteria for SLE or other SARDs. All received prednisone <10 mg/day and no immunosuppressants. Soluble SIGLEC1 was measu…
…Objectives Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus …
…ith active lupus nephritis compared with patients with inactive lupus nephritis (p=0.020).3) HUMARA assay, non-random XCI (>=70%) was more comm…
… outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor with broad modulatory effe…
…ided by directed acyclic graphs.Results Among 219 participants (SLE, pSS, SSc, IIM, MCTD, UCTD), IFN Scores A and B were the strong…
…O: 42.3% vs. 26.9%, RR 1.54 [1.18-2.00]).Conclusions Women with SLE have a lower rate of second pregnancy vs. the general populatio…
…e studied. At baseline, rheumatologists estimated RA risk (0–10 Numeric Rating Scale) informed by history, physical examination and laboratory resul…
…lori) infection may increase the risk of hypertension (HTN) and type 2 diabetes mellitus (T2D), but association studies have produced mixed results. Thi…